Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten; Michel W J M Wouters; Doranne L Hilarius; John B Haanen; Christian U Blank; Maureen J B Aarts; Franchette W P J van den Berkmortel; Jan-Willem B de Groot; Geke A P Hospers; Ellen Kapiteijn; Djura Piersma; Roos S van Rijn; Karijn P M Suijkerbuijk; Willeke A M Blokx; Bert-Jan J Ten Tije; Astrid A M van der Veldt; Art Vreugdenhil; Marye J Boers-Sonderen; Alfonsus J M van den Eertwegh

doi:10.1038/s41416-021-01312-1

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^V600-mutant advanced melanoma patients: a propensity-matched survival analysis

Br J Cancer. 2021 May;124(10):1746. doi: 10.1038/s41416-021-01312-1.

Authors

Jesper van Breeschoten^{1

2}, Michel W J M Wouters^{1

3}, Doranne L Hilarius⁴, John B Haanen⁵, Christian U Blank^{5

6}, Maureen J B Aarts⁷, Franchette W P J van den Berkmortel⁸, Jan-Willem B de Groot⁹, Geke A P Hospers¹⁰, Ellen Kapiteijn¹¹, Djura Piersma¹², Roos S van Rijn¹³, Karijn P M Suijkerbuijk¹⁴, Willeke A M Blokx¹⁵, Bert-Jan J Ten Tije¹⁶, Astrid A M van der Veldt¹⁷, Art Vreugdenhil¹⁸, Marye J Boers-Sonderen¹⁹, Alfonsus J M van den Eertwegh²⁰

Affiliations

¹ Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden, 2333AA, The Netherlands.
² Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, Amsterdam, 1081HZ, The Netherlands.
³ Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands.
⁴ Department of Pharmacy, Rode Kruis Ziekenhuis, Vondellaan 13, Beverwijk, 1942LE, The Netherlands.
⁵ Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands.
⁶ Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands.
⁷ Department of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, Maastricht, 6229 HX, The Netherlands.
⁸ Department of Medical Oncology, Zuyderland Medical Centre Sittard, Dr. H. van der Hoffplein 1, Sittard-Geleen, 6162BG, The Netherlands.
⁹ Isala Oncology Center, Isala, Dokter van Heesweg 2, Zwolle, 8025AB, The Netherlands.
¹⁰ Department of Medical Oncology, University Medical Centre Groningen, Hanzeplein 1, Groningen, 9713GZ, The Netherlands.
¹¹ Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333ZA, The Netherlands.
¹² Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, Enschede, 7512KZ, The Netherlands.
¹³ Department of Internal Medicine, Medical Centre Leeuwarden, Henri Dunantweg 2, Leeuwarden, 8934AD, The Netherlands.
¹⁴ Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht, 3584CX, The Netherlands.
¹⁵ Department of Pathology, Division of Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.
¹⁶ Department of Internal Medicine, Amphia Hospital, Molengracht 21, Breda, 4818CK, The Netherlands.
¹⁷ Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, 's-Gravendijkwal 230, Rotterdam, 3015CE, The Netherlands.
¹⁸ Department of Internal Medicine, Maxima Medical Centre, De Run 4600, Eindhoven, 5504DB, The Netherlands.
¹⁹ Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, Nijmegen, 6525GA, The Netherlands.
²⁰ Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, Amsterdam, 1081HZ, The Netherlands. vandeneertwegh@amsterdamumc.nl.

No abstract available

Publication types

Published Erratum